
Phase 2 trial results for the investigational vaccine were presented at IDWeek 2026 in Washington, DC, as the phase 3 program is currently underway.
Good Neighbor Pharmacy President Brian Nightengale explains how the shrinking availability of primary care physicians presents new opportunities for independent community pharmacists.






